Rhythm Pharmaceuticals Inc represents a strong commitment to improving the lives of people living with rare genetic disorders of obesity. The company focuses on developing and commercializing innovative therapies that address the underlying causes of these conditions. Rhythm Pharmaceuticals Inc prioritizes patient-driven research and collaboration with healthcare professionals to provide effective treatment options. With a dedicated team of experts, the company strives to make a positive impact in the lives of patients and their families. Through continuous innovation and a patient-centric approach, Rhythm Pharmaceuticals Inc remains at the forefront of developing transformative solutions in the field of rare genetic disorders of obesity.

Rhythm Pharmaceuticals Inc is primarily present in the United States.

Rhythm Pharmaceuticals Inc has achieved significant milestones since its establishment. Notably, the company successfully completed a Phase 3 clinical trial for its lead product, setmelanotide, which aims to treat rare genetic disorders of obesity. Additionally, Rhythm Pharmaceuticals Inc received approval from the U.S. Food and Drug Administration (FDA) for setmelanotide, marking a major achievement. This regulatory milestone reinforces the company's dedication to addressing the unmet needs of patients with genetic disorders of obesity. Rhythm Pharmaceuticals Inc's accomplishments demonstrate its commitment to developing innovative therapies for individuals affected by these challenging conditions.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of treatments for rare genetic disorders of obesity. Established in 2008, Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts. The company is focused on addressing the underlying biology of rare genetic disorders to provide innovative therapies for patients in need. With a dedicated team of scientists and researchers, Rhythm Pharmaceuticals strives to improve the lives of individuals affected by these disorders. Through its extensive research and clinical trials, the company aims to bring novel treatments to market that can make a significant impact on the global rare disease community.

The main competitors of Rhythm Pharmaceuticals Inc in the market include major players such as Amarin Corporation, Novo Nordisk A/S, and Eli Lilly and Company. These companies also operate in the pharmaceutical industry and offer products and solutions aimed at addressing various diseases and medical conditions. Despite facing tough competition, Rhythm Pharmaceuticals Inc continues to strive for innovation and excellence to establish its unique position and meet the growing needs of patients worldwide.

Rhythm Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Rhythm Pharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing treatments for rare genetic disorders of obesity. Their business model revolves around identifying and targeting specific genetic mutations that contribute to obesity-related disorders such as Prader-Willi Syndrome and other rare genetic disorders. Rhythm Pharmaceuticals Inc aims to develop and bring to market innovative therapies that address the underlying cause of these rare genetic disorders by targeting the melanocortin-4 receptor pathway. By leveraging their expertise in genetic research and drug development, Rhythm Pharmaceuticals Inc endeavors to provide effective and sustainable treatments for patients affected by these challenging disorders.

Pašreizējais KGV Rhythm Pharmaceuticals nevar tikt aprēķināts.

KUV šobrīd Rhythm Pharmaceuticals nevar aprēķināt.

AlleAktien kvalitātes vērtējums Rhythm Pharmaceuticals ir 6/10.

gaidāmā Rhythm Pharmaceuticals apgrozījums ir 178,88 milj. USD.

gaidāmā Rhythm Pharmaceuticals peļņa ir -172,49 milj. USD.

Rhythm Pharmaceuticals Inc. specializes in researching, developing, and marketing therapeutic solutions for metabolic diseases and disorders. The company focuses on treating rare, genetically-based diseases often accompanied by hormonal imbalances. They have become a leader in the development of medications for rare diseases. Their main focus is on treating obesity due to rare adipose types, known as POMC deficiency syndrome and LEPR deficiency syndrome. The company has two approved products for these conditions: setmelanotide and RM-853. Setmelanotide is a potent, selective melanocortin-4 receptor (MC4R) agonist approved by the FDA in 2020 for adults and children 6 years and older with POMC deficiency syndrome or LEPR deficiency syndrome. RM-853 is still in the clinical development phase. Rhythm Pharmaceuticals Inc. is a "One-Product-Company," meaning they focus their business model on just one product. They are actively working to improve the effectiveness of setmelanotide and gain approval for other medical indications, such as the melanocortin-4 receptor-deficient obesity phenotype, another rare obesity-related condition. The company is also working to improve setmelanotide production and reduce costs for patients to increase acceptance and usage among patients and physicians. Rhythm Pharmaceuticals Inc. is an innovative company that has focused on meeting the needs of rare diseases. They specialize in patients with rare obesity, often accompanied by hormonal disorders. Their expertise in developing therapies for metabolic diseases is impressive and supported by numerous patents held for their products. The business model of Rhythm Pharmaceuticals Inc. relies on their ability to focus on and dominate a niche. They primarily develop medications for rare diseases where there are no competing treatment options. The FDA approval of setmelanotide for POMC deficiency syndrome and LEPR deficiency syndrome demonstrates the company's ability to bring innovative therapies for rare diseases to market. In conclusion, Rhythm Pharmaceuticals Inc. focuses on developing therapies for rare, genetically-based metabolic diseases. They specialize in the field of obesity and have established themselves as leaders in treating obesity due to rare adipose types. Their business model is based on developing innovative medications for niche markets with no competing treatment options. Setmelanotide is their main product, exclusively approved for POMC deficiency syndrome and LEPR deficiency syndrome. The company is working to improve its effectiveness, explore other medical indications, and reduce costs for patients.

Rhythm Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Rhythm Pharmaceuticals vai uzņēmums nedod dividendes.

Rhythm Pharmaceuticals ISIN ir US76243J1051.

Rhythm Pharmaceuticals WKN ir A2H5A0.

Rhythm Pharmaceuticals simbols ir RYTM.

Pēdējo 12 mēnešu laikā Rhythm Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Rhythm Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Rhythm Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Rhythm Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Rhythm Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Rhythm Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Rhythm Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 16.07.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.07.2025..

Pēdējās dividendes izmaksa notika 16.07.2025..

Gadā 2024, Rhythm Pharmaceuticals izmaksāja 0 USD dividendes.

Rhythm Pharmaceuticals dividendes tiek izmaksātas USD.